Beam Therapeutics Inc. (BEAM) AI Stock Analysis

Beam Therapeutics Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, focused on advancing precision genetic medicines for severe diseases across the United States. Founded in 2017, the company uses CRISPR technology to create transformative therapies. Its clinical development pipeline includes BEAM-101 and BEAM-102 for sickle cell disease and beta thalassemia, BEAM-201 for relapsed/refractory T-cell acute lymphoblastic leukemia, and BEAM-301 for Glycogen Storage Disease Type Ia. Additionally, the company is advancing therapeutic programs targeting alpha-1 antitrypsin deficiency, ocular diseases, and disorders of the liver, muscle, and central nervous system through partnerships with organizations including Pfizer Inc., Apellis Pharmaceuticals, Inc., and Verve Therapeutics, Inc.

Beam Therapeutics has experienced large revenue swings over recent fiscal years. Top-line revenue surged 520.0% to $377.7M in FY2023, fell 83.2% to $63.5M in FY2024, and rose 120.0% to $139.7M in FY2025. Gross margin recovered from -478.7% in FY2024 to 84.0% in FY2025, while operating margin improved from -654.3% to -274.6%. Net income improved to -$80.0M in FY2025 compared to -$376.7M in FY2024, bringing diluted EPS from -$4.58 to -$1.01. Research and development expenses remained significant at $409.6M in FY2025. For the trailing twelve months ended June 30, 2026, revenue was $156.0M, but revenue fell 94.2% year-over-year in the quarter ended June 30, 2026.

As of June 30, 2026, Beam Therapeutics held $1.15B in cash and short-term investments compared to $247.4M in total debt, yielding net cash of $905.6M. Liquidity is supported by a current ratio of 14.57 and a debt-to-equity ratio of 0.23 against $1.07B in shareholders' equity. Operating cash flow was -$345.1M in FY2025, and with capital expenditures of $14.9M, free cash flow was -$360.0M. The company's share count increased 53.4% over the past five years.

At a closing price of $23.47 on October 16, 2026, Beam Therapeutics had a market cap of $2.42B and an enterprise value of $1.61B. The stock trades at a price-to-sales ratio of 15.5x and an EV-to-revenue multiple of 10.3x, above the median price-to-sales multiple of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 2.4x. Over the past year, the stock declined 9.0% compared to a 16.8% return for the S&P 500 (SPY). Over five years, the stock dropped 74.8% versus an 83.0% gain for the S&P 500.

Wall Street coverage includes 12 Strong Buy, 1 Buy, and 2 Hold ratings, with no Sell ratings. The mean price target is $52.15, which is 122.2% above the October 16, 2026 closing price of $23.47. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $48.6M and an EPS of -$4.45. Beam Therapeutics beat consensus EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 3, 2026.

This page is an AI-written research summary of Beam Therapeutics Inc. (BEAM). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BEAM income statement, BEAM balance sheet, BEAM key metrics, BEAM analyst forecast, BEAM chart. See the BEAM stock overview for the latest quote and news.